Gland Pharma Limited (NSE:GLAND) submitted the transcript of its Q1 FY27 earnings conference call to the exchanges on 17 August 2026. The call, held on 10 August 2026, disclosed revenues of INR18,003 million for the quarter ended 30 June 2026, representing 20% year-on-year growth.
Key Highlights
- Q1 FY27 consolidated revenues reached INR18,003 million, up 20% year-on-year, as stated by Executive Chairman Srinivas Sadu during the call.
- Adjusted EBITDA for Q1 FY27 was INR5,102 million at a margin of 28%, while profit after tax stood at INR3,170 million, up 47% year-on-year with an 18% PAT margin.
- The CDMO segment generated revenues of INR8,915 million, growing 20% year-on-year and contributing 50% of total revenues for the quarter.
- The B2B business contributed the remaining 50% of revenues at INR9,088 million, recording 19% year-on-year growth supported by new contract wins and higher product volumes.
About the Company
Gland Pharma Limited (NSE:GLAND), headquartered in Hyderabad, Telangana, is an injectable-focused pharmaceutical manufacturer incorporated in 1978 under CIN L24239TG1978PLC002276. The company operates across sterile injectables, CDMO services, and B2B pharmaceutical supply, serving regulated markets globally including the United States, Europe, and rest-of-world geographies from its manufacturing facilities in Telangana.
Announcement in Detail
The transcript was filed by Company Secretary and Compliance Officer Sampath Kumar Pallerlamudi on 17 August 2026, covering the earnings call conducted on Monday, 10 August 2026 at 18:30 hrs IST. The call was led by Executive Chairman Srinivas Sadu and Chief Financial Officer Ravi Mitra, with Shriniwas P. Dange, Head of Investor Relations, moderating proceedings. The transcript is accessible on the company's investor relations page at glandpharma.com/investors/financials.
During the call, management attributed Q1 FY27 revenue growth to contributions from recent product launches, volume increases in existing products, improved capacity utilisation, and operational efficiency initiatives across the organisation. The CDMO segment, which stood at INR8,915 million, grew on the back of commercial programme progression and new customer engagements with global pharmaceutical companies seeking sterile manufacturing partners. The B2B segment at INR9,088 million benefited from new contract wins and deeper customer relationships across select markets.
Impact on Investors
The filing shows that both the CDMO and B2B segments contributed equally to total revenues at 50% each, providing shareholders a view of the diversified revenue composition for Q1 FY27. Investors will note that the 47% year-on-year rise in profit after tax, alongside an EBITDA margin of 28%, reflects the operating leverage management cited from improved capacity utilisation and disciplined cost management. The disclosed PAT margin of 18% provides context on the company's current profitability profile within its injectable manufacturing business.
Shareholders will observe that the transcript itself does not contain specific forward guidance on revenue targets, capital expenditure plans, or dividend declarations for FY27. The filing is informational in nature and does not alter the company's stated capital structure or shareholder entitlements as of the filing date.
Sector / Market Context
India's pharmaceutical exports have consistently placed the country among the top global suppliers of generic and sterile injectable formulations. According to the Pharmaceuticals Export Promotion Council of India (Pharmexcil), injectable formulations remain one of the higher-value export categories for Indian manufacturers. CDMO activity in India has expanded in recent years as global pharmaceutical companies seek to diversify their sterile manufacturing supply chains, a structural trend that has supported capacity investments by companies operating in this segment.